Clinical Read2026-06-01

IMFINZI (Durvalumab) + TACE - (EMERALD-3)

AstraZeneca PLCAZN
Indication
Locoregional Hepatocellular carcinoma (HCC)
Stage
phase3
Event
Phase 3